Search Result

Results for "

DOPA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (7) Adenosine Receptor (1) Adrenergic Receptor (5) Antibiotic (1) Arrestin (1) Bacterial (1) Biochemical Assay Reagents (2) Carboxypeptidase (1) COMT (3) DNA/RNA Synthesis (2) Dopamine Receptor (28) Dopamine Transporter (1) Drug Derivative (2) Drug Intermediate (1) Drug Metabolite (6) Endogenous Metabolite (18) GABA Receptor (3) Glycosidase (1) HIV (1) iGluR (1) Imidazoline Receptor (5) Interleukin Related (4) Isotope-Labeled Compounds (8) Liposome (1) mGluR (2) Monoamine Oxidase (6) nAChR (3) OAT (2) Opioid Receptor (5) Pyruvate Kinase (4) Reactive Oxygen Species (ROS) (1) Reference Standards (10) Serotonin Transporter (1) Tyrosinase (7) Tyrosine Hydroxylase (5)
By Research Areas:	Cancer (14) Endocrinology (2) Infection (2) Inflammation/Immunology (11) Metabolic Disease (4) Neurological Disease (57)

By Targets:

5-HT Receptor (7)

Adenosine Receptor (1)

Adrenergic Receptor (5)

Antibiotic (1)

Arrestin (1)

Bacterial (1)

Biochemical Assay Reagents (2)

Carboxypeptidase (1)

COMT (3)

DNA/RNA Synthesis (2)

Dopamine Receptor (28)

Dopamine Transporter (1)

Drug Derivative (2)

Drug Intermediate (1)

Drug Metabolite (6)

Endogenous Metabolite (18)

GABA Receptor (3)

Glycosidase (1)

HIV (1)

iGluR (1)

Imidazoline Receptor (5)

Interleukin Related (4)

Isotope-Labeled Compounds (8)

Liposome (1)

mGluR (2)

Monoamine Oxidase (6)

nAChR (3)

OAT (2)

Opioid Receptor (5)

Pyruvate Kinase (4)

Reactive Oxygen Species (ROS) (1)

Reference Standards (10)

Serotonin Transporter (1)

Tyrosinase (7)

Tyrosine Hydroxylase (5)

By Research Areas:

Cancer (14)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (11)

Metabolic Disease (4)

Neurological Disease (57)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

DL-Dopa	Endogenous Metabolite	Others
DL-Dopa is a beta-hydroxylated derivative of phenylalanine.

L-DOPA Maximum Cited Publications 27 Publications Verification LevoDOPA; 3,4-Dihydroxyphenylalanine	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

*6-Hydroxy-DOPA* (Standard)**	DNA/RNA Synthesis	Cancer
6-Hydroxy-DOPA (Standard) is the analytical standard of 6-Hydroxy-DOPA. This product is intended for research and analytical applications. 6-Hydroxy-DOPA is a selective and effective allosteric inhibitor of the RAD52 ssDNA binding domain. 6-Hydroxy-DOPA can be used for the research of cancer .

6-Hydroxy-DOPA	DNA/RNA Synthesis	Cancer
6-Hydroxy-DOPA is a selective and effective allosteric inhibitor of the RAD52 ssDNA binding domain. 6-Hydroxy-DOPA can be used for the research of cancer .

*6-Hydroxy-L-DOPA* (Standard)**	Reference Standards Biochemical Assay Reagents	Others
6-Hydroxy-L-DOPA (Standard) is the analytical standard of 6-Hydroxy-L-DOPA. This product is intended for research and analytical applications. 6-Hydroxy-L-DOPA is a nucleic acid functionalized with electron-donating units .

*L-DOPA* sodium** LevoDOPA sodium; 3,4-Dihydroxyphenylalanine sodium	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .

*L-DOPA* (Standard)** LevoDOPA (Standard); 3,4-Dihydroxyphenylalanine (Standard)	Reference Standards Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

6-Hydroxy-L-DOPA	Biochemical Assay Reagents	Others
6-Hydroxy-L-DOPA is a nucleic acid functionalized with electron-donating units .

*[18F]-Labeled L-dopa* precursor**	Dopamine Receptor	Others
[18F]-Labeled L-dopa precursor is a precursor for synthesis of 18F-labeled L-dopa extracted from patent WO2014095739A1, example 8 .

D-Dopa 3-Hydroxy-D-tyrosine	Carboxypeptidase	Neurological Disease
D-Dopa is a non-competitive, allosteric inhibitor for glutamate carboxypeptidase II (GCPII) with an IC₅₀ of 200 nM. D-Dopa exhibits good pharmacokinetic characteristics, and low blood-brain barrier permeability in mouse model .

*3-O-Methyl-DL-DOPA* (Standard)** 3-Methoxytyrosine (Standard)	Endogenous Metabolite Reference Standards	Neurological Disease
3-O-Methyl-DL-DOPA (Standard) is the analytical standard of 3-O-Methyl-DL-DOPA. This product is intended for research and analytical applications. 3-O-Methyl-DL-DOPA is an endogenous metabolite present in Cerebrospinal_Fluid that can be used for the research of Epilepsy, Purine Nucleoside Phosphorylase Deficiency and Aromatic L Amino Acid Decarboxylase Deficiency [4].

Phenylthiourea Phenylthiocarbamide	Tyrosinase Endogenous Metabolite	Others
Phenylthiourea (Phenylthiocarbamide) is an inhibitor for phenoloxidase. Phenylthiourea inhibits enzymatic oxidation of DOPA by phenoloxidase (K_i = 0.21 μM). Phenylthiourea is an effective inhibitor for tyrosinase. Phenylthiourea can lead to graying of hair in black rats due to the interference with melanin formation .

α-Methyl-p-tyrosine 1 Publications Verification	Tyrosine Hydroxylase	Neurological Disease Cancer
α-Methyl-p-tyrosine is a competitive inhibitor of tyrosine hydroxylase, which converts tyrosine into DOPA. α-Methyl-p-tyrosine is also an orally active inhibitor of catecholamine synthesis, inhibiting the hydroxylation of tyrosine into DOPA. α-Methyl-p-tyrosine can be used in research related to epilepsy, glaucoma, cancer, and other related diseases .

3-O-Methyl-DL-DOPA 3-Methoxytyrosine	Endogenous Metabolite	Neurological Disease
3-O-Methyl-DL-DOPA is an endogenous metabolite present in Cerebrospinal_Fluid that can be used for the research of Epilepsy, Purine Nucleoside Phosphorylase Deficiency and Aromatic L Amino Acid Decarboxylase Deficiency .

Etilevodopa hydrochloride L-DOPA ethyl ester hydrochloride; LevoDOPA ethyl ester hydrochloride	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

Etilevodopa L-DOPA ethyl ester; LevoDOPA ethyl ester	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

3-O-Methyldopa monohydrate 1 Publications Verification 3-Methoxy-L-tyrosine monohydrate; 3-O-Methyl-L-DOPA monohydrate	COMT	Neurological Disease
3-O-Methyldopa monohydrate (3-Methoxy-L-tyrosine monohydrate) is a significant metabolite of L-DOPA produced through the action of catechol O-methyltransferase (COMT). Unlike its precursor, 3-O-Methyldopa does not serve as a substrate or inhibitor of L-amino acid decarboxylase activity. Additionally, the inhibition of COMT can amplify the anti-Parkinson effects of L-DOPA.

α-Methyl-p-tyrosine (Standard)	Tyrosine Hydroxylase	Neurological Disease Cancer
α-Methyl-p-tyrosine (Standard) is the analytical standard of α-Methyl-p-tyrosine. This product is intended for research and analytical applications. α-Methyl-p-tyrosine is a competitive inhibitor of tyrosine hydroxylase, which converts tyrosine into DOPA. α-Methyl-p-tyrosine is also an orally active inhibitor of catecholamine synthesis, inhibiting the hydroxylation of tyrosine into DOPA. α-Methyl-p-tyrosine can be used in research related to epilepsy, glaucoma, cancer, and other related diseases .

3-O-Methyldopa 1 Publications Verification 3-Methoxy-L-tyrosine; 3-O-Methyl-L-DOPA	Drug Derivative Interleukin Related	Neurological Disease Inflammation/Immunology
3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .

Etilevodopa hydrochloride (Standard) L-DOPA ethyl ester hydrochloride (Standard); LevoDOPA ethyl ester hydrochloride (Standard)	Reference Standards Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (hydrochloride) (Standard) is the analytical standard of Etilevodopa (hydrochloride). This product is intended for research and analytical applications. Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine[1][2][3].

3-O-Methyldopa-d3 hydrate 3-Methoxy-L-tyrosine-d₃ hydrate; 3-O-Methyl-L-DOPA-d₃ hydrate	Isotope-Labeled Compounds Drug Metabolite Interleukin Related	Neurological Disease Inflammation/Immunology
3-O-Methyldopa-d₃ (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) hydrate is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa hydrate inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa hydrate has certain antidepressant and neuroprotective activities. 3-O-Methyldopa hydrate can be used in the research of nervous system diseases such as depression and Parkinson's disease .

3-O-Methyldopa-d3 3-Methoxy-L-tyrosine-d₃; 3-O-Methyl-L-DOPA-d₃	Isotope-Labeled Compounds Drug Metabolite Interleukin Related	Neurological Disease Inflammation/Immunology
3-O-Methyldopa-d₃ (3-Methoxy-L-tyrosine-d₃) is deuterium labeled 3-O-Methyldopa (HY-113468A). 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .

2-Fluorodeoxyarbutin	Tyrosine Hydroxylase	Metabolic Disease
2-Fluorodeoxyarbutin, a derivative of Deoxyarbutin (HY-B1461), is a tyrosine hydroxylase and dopa oxidase inhibitor. 2-Fluorodeoxyarbutin inhibits melanin synthesis in intact melanocytes. 2-Fluorodeoxyarbutin can be used for the strudy of skin lightening or for ameliorating hyperpigmented lesions .

TAS-4	iGluR	Neurological Disease
TAS-4 is a potent and selective mGluR4 positive allosteric modulator with significant anti-Parkinson's disease activity. TAS-4 is able to show efficacy when used alone or in combination with l-DOPA. TAS-4 is able to reverse haloperidol-induced spasticity when administered alone. TAS-4 enhances the contralateral rotation behavior induced by l-DOPA in a dose-dependent manner. TAS-4 combined with low-dose l-DOPA shows anti-Parkinson's effects similar to full-dose l-DOPA without exacerbating abnormal motor side effects .

Nebicapone BIA 3-202	COMT	Metabolic Disease
Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease .

DMNB 6-Nitroveratraldehyde	Drug Intermediate	Neurological Disease
DMNB (6-Nitroveratraldehyde), a precursor, can be used for the synthesis no-carrier-added 6-[ ¹⁸F]fluoro-L-DOPA (6-FDOPA). No-Carrier-Added (NCA) 6-[18F]fluoro-L-dopa (6-FDOPA) is being produced routinely for PET investigations of dopaminergic systems .

Nebicapone (Standard) BIA 3-202 (Standard)	Reference Standards COMT	Metabolic Disease
Nebicapone (Standard) is the analytical standard of Nebicapone. This product is intended for research and analytical applications. Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease .

3-O-Methyldopa (Standard)	Drug Derivative Interleukin Related	Neurological Disease Inflammation/Immunology
3-O-Methyldopa (Standard) is the analytical standard of 3-O-Methyldopa. This product is intended for research and analytical applications. 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine .

2-Bromo-LSD BOL-148; Bromolysergide	Dopamine Receptor 5-HT Receptor	Neurological Disease
2-Bromo-LSD (BOL-148; Bromolysergide) is a Dopamine Receptor antagonist that directly affects dopamine neurons in the substantia nigra neostriatum. 2-Bromo-LSD increases the hydroxylation of tyrosine in striatum and antagonizes the decrease of Apomorphine-induced DOPA accumulation. 2-Bromo-LSD also blocks the 5-HT Receptor mediated DOPA formation .

Baculiferin A	HIV	Infection
Baculiferins A is a DOPA-derived pyrrole alkaloid. Baculiferins A can be isolated from the Chinese marine sponge Iotrochota baculifera. Baculiferins A have anti-HIV activity .

Etilevodopa (Standard) L-DOPA ethyl ester (Standard); LevoDOPA ethyl ester (Standard)	Reference Standards Dopamine Receptor Drug Metabolite	Neurological Disease
Chlorbenside (Standard) is the analytical standard of Chlorbenside. This product is intended for research and analytical applications. Chlorbenside is an organochlorine pesticide. Chlorbenside targets organism such as mites and ticks and possesses efficient ovicidal and larvicidal activities .

LY 165163 p-NH2-PE-TFMPP	5-HT Receptor	Neurological Disease
LY 165163 is a potent 5-HT presynaptic receptor agonist. LY 165163 significantly decreases 5-HTP accumulation and increases DOPA accumulation in the cortex and striatum .

Sarizotan hydrochloride EMD 128130 hydrochloride	5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan hydrochloride is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan hydrochloride (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

Sarizotan dihydrochloride EMD 128130 dihydrochloride	5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan dihydrochloride (EMD 128130) is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

Sarizotan (Standard) EMD 128130 (Standard)	Reference Standards 5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan (Standard) is the analytical standard of Sarizotan. This product is intended for research and analytical applications. Sarizotan (EMD 128130) is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

Sarizotan 1 Publications Verification EMD 128130	5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan (EMD 128130) is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

3-(2,4-Dihydroxyphenyl)propanoic acid	Tyrosinase Endogenous Metabolite	Others
3-(2,4-Dihydroxyphenyl)propanoic acid (DPPacid) is a potent and competitive tyrosinase inhibitor, inhibits L-Tyrosine and DL-DOPA with an IC₅₀ and a K_i of 3.02 μM and 11.5 μM, respectively .

Cat. No.	Product Name	Target	Research Area

HY-W096171

D-Dopa 3-Hydroxy-D-tyrosine	Carboxypeptidase	Neurological Disease
D-Dopa is a non-competitive, allosteric inhibitor for glutamate carboxypeptidase II (GCPII) with an IC₅₀ of 200 nM. D-Dopa exhibits good pharmacokinetic characteristics, and low blood-brain barrier permeability in mouse model .

HY-P1335A

CTAP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-W152604

Cyclo(glycyl-L-leucyl) Cyclo(leu-gly)	Dopamine Receptor	Neurological Disease
Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .

HY-P1335

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

Species:	Human (3) Mouse (1)
Tag:	His (3) Tag Free (1) Strep (1)
Source:	sf9 insect cells (1) Sf9 insect cells (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701909

	DDC Protein, Human DDC; Aromatic-L-amino-acid decarboxylase; AADC; DOPA decarboxylase; DDC	Human	E. coli
	DDC protein plays a central role in neurotransmitter synthesis by catalyzing the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to produce dopamine and L-5-hydroxytryptophan to produce serotonin. DDC Protein, Human is the recombinant human-derived DDC protein, expressed by E. coli , with tag free.

HY-P74204

	DDC Protein, Mouse (sf9, His) Aromatic-L-amino-acid decarboxylase; AADC; DOPA decarboxylase; DDC	Mouse	Sf9 insect cells
	The DDC protein plays a key role in neurotransmitter synthesis as it catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to produce dopamine and L-5-hydroxytryptophan to produce serotonin. These enzymatic reactions represent key steps in neurotransmitter biosynthesis and are essential for the normal functioning of the central nervous system. DDC Protein, Mouse (sf9, His) is the recombinant mouse-derived DDC protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P701910

	DDC Protein, Human (His, Strep II) DDC; Aromatic-L-amino-acid decarboxylase; AADC; DOPA decarboxylase; DDC	Human	E. coli
	DDC protein plays a central role in neurotransmitter synthesis by catalyzing the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to produce dopamine and L-5-hydroxytryptophan to produce serotonin. DDC Protein, Human (His, Strep II) is the recombinant human-derived DDC protein, expressed by E. coli , with N-Strep II, N-6*His labeled tag.

HY-P704655

	DDC Protein, Human (Sf9, His) DDC; Aromatic-L-amino-acid decarboxylase; AADC; DOPA decarboxylase; DDC	Human	sf9 insect cells
	DDC protein plays a central role in neurotransmitter synthesis by catalyzing the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to produce dopamine and L-5-hydroxytryptophan to produce serotonin. DDC Protein, Human (Sf9, His) is the recombinant human-derived DDC protein, expressed by sf9 insect cells, with C-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-N0304S2

*L-DOPA-13C* 1 Publications Verification
L-DOPA- ¹³C is the ¹³C labeled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-132392S

*L-DOPA-2,5,6-d3*
L-DOPA-2,5,6-d₃ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain .

HY-132404S

*(rac)-3-O-Methyl DOPA-d3*
(rac)-3-O-Methyl DOPA-d₃ is the deuterium labeled (rac)-3-O-Methyl DOPA .

HY-N0304S

*L-DOPA-d6*
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-113468AS

3-O-Methyldopa-d3

3-O-Methyldopa-d₃ (3-Methoxy-L-tyrosine-d₃) is deuterium labeled 3-O-Methyldopa (HY-113468A). 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .

HY-113404S

*DL-Dopa-d6*
DL-Dopa-d₆ is the deuterium labeled DL-Dopa. DL-Dopa is a beta-hydroxylated derivative of phenylalanine.

HY-113404S1

*L-Dopa-d3*
L-Dopa-d₃ is deuterated labeled DL-Dopa (HY-113404). DL-Dopa is a beta-hydroxylated derivative of phenylalanine.

HY-N0304S1

*L-DOPA-13C6*
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-113468AS1

3-O-Methyldopa-d3 hydrate

3-O-Methyldopa-d₃ (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) hydrate is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa hydrate inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa hydrate has certain antidepressant and neuroprotective activities. 3-O-Methyldopa hydrate can be used in the research of nervous system diseases such as depression and Parkinson's disease .

HY-W401531S

(R)-3-O-Methyldopa-d3
(R)-3-O-Methyldopa-d₃ is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine .

HY-W401531S1

(R)-3-O-Methyldopa-d3 hydrochloride
(R)-3-O-Methyldopa-d₃ (hydrochloride) is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine .

HY-B0404AS

Benserazide-d3 hydrochloride

Benserazide-d₃ (hydrochloride) is the deuterium labeled Benserazide hydrochloride (HY-B0404A). Benserazide hydrochloride (Serazide) is an aromatic L-amino acid decarboxylase (AADC) and L-DOPA decarboxylase inhibitor. Benserazide hydrochloride is also a PKM2 inhibitor. Benserazide hydrochloride directly binds to and blocks PKM2 enzyme activity, leading to inhibition of aerobic glycolysis concurrent up-regulation of OXPHOS. Benserazide hydrochloride can be used for the study of Parkinson's disease and melanoma .

HY-W700834

Harman-d3

Harman-d₃ is deuterium labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-W777360

Harman-13C2,15N

Harman- ¹³C₂, ¹⁵N is ¹³C and ¹⁵N labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82683

	DOPA Decarboxylase Antibody (YA2428) AADC; Aromatic L Amino Acid Decarboxylase; DDC; DOPA decarboxylase (aromatic L-amino acid decarboxylase); DOPA decarboxylase	WB	Human, Mouse, Rat
	DOPA Decarboxylase Antibody (YA2428) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DOPA Decarboxylase.